Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
Eva C Coopmans1, Sebastiaan W F van Meyel1, Kay J Pieterman2
1Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands.
Abstract:
Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas.
Related Concept Videos
Aggression
Microsoft Excel: Plotting Mean, SD, and SE
First, calculate the mean, SD, and SE of your data. The mean is obtained using the formula `=AVERAGE(range)`, while SD can be calculated with `=STDEV.P(range)` for a population or `=STDEV.S(range)` for a sample. SE is calculated as `=SD/SQRT(n)`, where `n` is the sample size.
To plot these values, use a bar...
Microsoft Excel: Student's t-Test
To conduct a t-test in Excel, use the T.TEST function or the "Data...
Microsoft Excel: Pearson's Correlation
Microsoft Excel: Regression Analysis
To perform regression...
Overview of Microsoft Excel as a Data Analysis Tool


